• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine tablet in the pipeline

kiwibird

kiwibird

Editor, Senior Moderator
https://www.europeanpharmaceuticalr...et-safely-induces-immune-response-in-phase-i/
Merck
NEWS
Investigational COVID-19 vaccine tablet safely induces immune response in Phase I
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
Click to expand...

https://www.researchprofessionalnew...-2-covid-vaccine-pill-enters-clinical-trials/

US and South Africa trials test oral vaccine whose capsule technology was developed in UK

A US-based company, ImmunityBio, has acquired worldwide rights to technology developed in the UK to deliver Covid-19 vaccines in a pill or tablet form, and has now started clinical trials.

ImmunityBio?s human adenovirus (hAd5) Covid-19 vaccine candidate is being tested in people in South Africa as well as in the US, following successful tests in non-human primates.

The vaccine is designed to activate the immune system through virus-specific T-cells and to generate memory B-cells with neutralising antibodies, which ImmunityBio says could protect against emerging coronavirus mutations.
Click to expand...

An interview this morning on BBC News indicated that it is likely that the booster vaccine required for the autumn in the UK to cover the variants circulating would be supplied by tablet "through the post".
 
You must log in or register to reply here.
Back
Top Bottom